Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | PNMT | P11086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26664086 | 0.76 | ALDH1A1 (0.40) | HSD17B10 | |
| SCHEMBL3924964 | 0.74 | — | — | |
| SCHEMBL26667759 | 0.67 | BRD4 (0.50) | BRD4HSD17B10 | |
| SCHEMBL6921365 | 0.63 | BRD4 (0.40) | GRIA2BRD4HSD17B10 | |
| SCHEMBL11502519 | 0.62 | GRIA1 (0.45) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL26667857 | 0.61 | BRD4 (0.39) | BRD4 | |
| SCHEMBL8054291 | 0.60 | MAOA (0.44) | PNMT | |
| SCHEMBL18100472 | 0.60 | GRIA1 (0.31) | GRIA1GRIA2GRIA3GRIA4 | |
| SCHEMBL8157650 | 0.59 | BRD4 (0.50) | BRD4 | |
| SCHEMBL18152883 | 0.58 | BRD4 (0.49) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | GRIA1 438/4885GRIA2 488/4885GRIA3 519/4885 |
| US-20140200215-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | GRIA1 438/4885GRIA2 488/4885GRIA3 519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.